Comparative Pharmacology
Head-to-head clinical analysis: SEPTRA GRAPE versus XIMINO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEPTRA GRAPE versus XIMINO.
SEPTRA GRAPE vs XIMINO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Septra Grape (trimethoprim/sulfamethoxazole) inhibits bacterial folic acid synthesis via sequential blockade: sulfamethoxazole inhibits dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
XIMINO is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
160 mg trimethoprim / 800 mg sulfamethoxazole (1 double-strength tablet) orally every 12 hours.
400 mg orally twice daily with food for 7 days.
None Documented
None Documented
Trimethoprim: 8-10 hours (renal impairment >24h). Sulfamethoxazole: 10-13 hours (acetylation phenotype; prolonged in renal impairment). Clinical: Dosing interval generally 12h; adjust CrCl <30 mL/min.
Terminal elimination half-life: 8 hours (range 6-10 hours) in healthy adults; prolonged to 15-20 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 50-70% unchanged (trimethoprim), 30-50% as N-acetyl metabolite; sulfamethoxazole: 70-80% as metabolites, 20-30% unchanged; biliary excretion minimal (<5% total).
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites and unchanged drug; 10% metabolized via hepatic CYP3A4.
Category C
Category C
Antibiotic
Antibiotic